K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
复制标题
在非小细胞肺癌患者中，K-RAS和p53突变是独立的不利预后指标。
DOI：
10.1038/bjc.1997.194
复制
发表时间：
1997
影响因子：
8.8
通讯作者：
Sugimachi K
中科院分区：
文献类型：
--
作者：
Fukuyama Y;Mitsudomi T;Sugio K;Ishida T;Akazawa K;Sugimachi K
我们连续检测了159例非小细胞肺癌(NSCLC)K-ras基因第12密码子的突变和第5-8外显子的p53基因突变。K-ras(ras+)突变11例(6.9%)，p53(p53+)突变57例(35.8%)。Ras-P53-95例(59.7%)，ras+/P53-7例(4.4%)，ras-/P53+53例(33.3%)，ras+/P53+4例(2.5%)。在所有病例和107例早期病例中，ras+组的预后均比ras组差(I-II期，P<0.05)。在107例早期患者中，P53+组预后较差(P<；0.01)，但在52例晚期(III-IV期)或全部患者中，P53+组的预后差异无统计学意义。在94例腺癌中，ras和p53基因突变均为不良预后因素，而在57例鳞癌中，ras和p53突变均无统计学意义。根据Cox模型，病理分期、ras基因突变和p53基因突变是影响预后的独立因素。我们的结果提示ras和p53突变是独立的预后不良标志物，特别是在NSCLC的早期或腺癌中。
We examined 159 consecutive cases of non-small-cell lung cancer (NSCLC) for a mutation at codon 12 of the K-ras gene and for a mutation of the p53 gene occurring in exons 5-8. Eleven (6.9%) had mutations of the K-ras (ras+) and 57 (35.8%) had mutations of the p53 (p53+). There were 95 cases (59.7%) with ras- p53-, seven cases (4.4%) with ras+/p53-, 53 cases (33.3%) with ras-/p53+ and four cases (2.5%) with ras+/p53+. The ras+ group had a worse prognosis than the ras group in all cases and in 107 early-stage cases (stage I-II, P<0.05). The p53+ group had a worse prognosis in 107 early-stage cases (P<0.01), but there was no statistically significant difference when 52 advanced-stage cases (stage III-IV) or all patients were considered. Both ras and p53 mutations were unfavourable prognostic factors in 94 cases with adenocarcinoma, but there was no statistical significance in 57 cases with squamous cell carcinoma. According to Cox's model, the pathological stage, ras mutation and p53 mutation were found to be independent prognostic factors. Our results suggest that ras and p53 mutations were independent unfavourable prognostic markers especially in the early stage of NSCLC or in adenocarcinoma.